Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Griesinger, Georg ^a   Verweij, Pierre J M ^b   Gates, Davis ^c   Devroey, Paul ^d   Gordon, Keith ^c   Stegmann, Barbara J ^c   Tarlatzis, Basil C ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b MSD Oss BV   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CORIFOLLITROPIN ALFA; ESTRADIOL; GANIRELIX; RECOMBINANT FOLLITROPIN; FOLLICLE STIMULATING HORMONE, HUMAN, WITH HCG C-TERMINAL PEPTIDE; FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; EMBRYO; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE CELL; OVARY HYPERSTIMULATION; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; ADOLESCENT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; ORGAN SIZE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY FOLLICLE; OVULATION INDUCTION; PATHOLOGY; PREGNANCY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CHORIONIC GONADOTROPIN; CLINICAL TRIALS AS TOPIC; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; ORGAN SIZE; OVARIAN FOLLICLE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84961140541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149615     Document Type: Article

References (28)

1. Klemetti R, Sevon T, Gissler M, Hemminki E (2005) Complications of IVF and ovulation induction. Hum Reprod 20: 3293-3300. PMID: 16126753.
2. Alper MM, Smith LP, Sills ES (2009) Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management. J Exp Clin Assist Reprod 6: 3. PMID: 20485578.
3. Tarlatzis BC, Griesinger G, Leader A, Rombauts L, Ijzerman-Boon PC, Mannaerts BM (2012) Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 24: 410-419. doi: 10.1016/j.rbmo.2012.01.005 PMID: 22386594.
4. Delbaere A, Smits G, De Leener A, Costagliola S, Vassart G (2005) Understanding ovarian hyperstimulation syndrome. Endocrine 26: 285-290. PMID: 16034183.
5. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM (2000) Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73: 901-907. PMID: 10785214.
6. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G (2006) Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-Analysis. Hum Reprod Update 12: 651-671. PMID: 16920869.
7. The corifollitropin alfa Ensure study group (2010) Corifollitropin alfa for ovarian stimulation in IVF: A randomized trial in lower-body-weight women. Reprod Biomed Online 21: 66-76. doi: 10.1016/j.rbmo. 2010.03.019 PMID: 20483664.
8. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC (2009) A doubleblind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24: 3063-3072. doi: 10. 1093/humrep/dep291 PMID: 19684043.
9. Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B (2011) Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 26: 2200-2208. doi: 10.1093/humrep/der163 PMID: 21622693.
10. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P (2006) Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85: 112-120. PMID: 16412740.
11. Agents stimulating gonadal function in the human. Report of a WHO scientific group. World Health Organ Tech Rep Ser 514: 1-30. PMID: 4632594.
12. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB (2007) Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 5: 9. PMID: 17362511.
13. Kahnberg A, Enskog A, Brannstrom M, Lundin K, Bergh C (2009) Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Acta Obstet Gynecol Scand 88: 1373-1381. doi: 10.3109/00016340903287482 PMID: 19878052.
14. Delvigne A, Rozenberg S (2002) Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 8: 559-577. PMID: 12498425.
15. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-Antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: A meta-Analysis. Reprod Biomed Online 13: 628-638. PMID: 17169171.
16. Kol S (2004) Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81: 1-5.
17. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al Hasani S, Schultze-Mosgau A (2007) Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: A prospective, observational proof-of-concept study. Hum Reprod 22: 1348-1352. PMID: 17303632.
18. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S (2011) Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-All" strategy: A prospective multicentric study. Fertil Steril 95: 2029-2033. doi: 10.1016/j.fertnstert.2011.01.163 PMID: 21371705.
19. Manzanares MA, Gomez-Palomares JL, Ricciarelli E, Hernandez ER (2010) Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril 93: 1215- 1219. doi: 10.1016/j.fertnstert.2008.12.019 PMID: 19200978.
20. Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP (2014) Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-Analysis of randomized controlled trials. Fertil Steril 101: 664-675. doi: 10.1016/j.fertnstert.2013.11.005 PMID: 24360566.
21. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ (2012) Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2: CD008605. doi: 10.1002/14651858. CD008605.pub2 PMID: 22336848.
22. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR (2014) Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 11: CD006105. doi: 10.1002/14651858.CD006105.pub3 PMID: 25406011.
23. Fadini R, Dal Canto MB, Mignini RM, Brambillasca F, Comi R, Fumagalli D, Lain M, Merola M, Milani R, De Ponti E (2009) Effect of different gonadotrophin priming on IVM of oocytes from women with normal ovaries: A prospective randomized study. Reprod Biomed Online 19: 343-351. PMID: 19778479.
24. Gremeau AS, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, Child T (2012) In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertil Steril 98: 355-360. doi: 10.1016/j.fertnstert.2012.04.046 PMID: 22658347.
25. Junk SM, Yeap D (2012) Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. Fertil Steril 98: 888-892. doi: 10.1016/j.fertnstert.2012.06.055 PMID: 22835445.
26. Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL (2002) A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 100: 665-670. PMID: 12383531.
27. Walls ML, Hunter T, Ryan JP, Keelan JA, Nathan E, Hart RJ (2015) In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: A comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod 30: 88-96. doi: 10.1093/humrep/deu248 PMID: 25355587.
28. Devroey P, Polyzos NP, Blockeel C (2011) An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 26: 2593-2597. doi: 10.1093/humrep/der251 PMID: 21828116.